Blue Light Cystoscopy with Cysview® demonstrates cost-effectiveness

A new study published by Dr. J. Stephen Jones and colleagues in The Canadian Journal of Urology™, 20(2); April 2013 demonstrated that by including Blue Light Cystoscopy with Cysview® (BLC) as adjunct to White Light Cystoscopy (WLC) may be cost saving for providers and payers. The overall cancer burden over five years was also improved.

The objective of the study was to conduct a detailed assessment of the cost effectiveness of using hexaminolevulinate hydrochloride (Cysview®) with Blue Light Cystoscopy (BLC) as an adjunct to white light versus White Light Cystoscopy alone (WLC) at the time of transurethral resection of bladder tumors (TURB) for patients in the United States with suspected or recurrent non-muscle invasive papillary bladder cancer (NMIBC. A probabilistic decision tree model using TreeAge Pro 2011 was developed using base case scenario cost and utility estimates.

The model was built from a payer perspective and captures costs of diagnosis, treatment and follow-up surveillance over a five year period for a cohort of patients. Published 2012 data from Medicare and private payer data sources were used to estimate cost and amounts for reimbursement. The Grossman study1 was the primary data source used within the model to predict clinical events. Costs for treatment of side effects were not considered but well conducted clinical studies, such as Grossmann et al, suggest that side effects are transient and mild or moderate.

The model findings demonstrate cost savings and clinical improvements with Blue Light Cystoscopy with Cysview®, and the authors conclude that including Cysview® as the standard of care for detection of NMIBC may result in cost saving for payers and providers:
BLC with Cysview® patients cost 15% less, per patient on average, over five years than patients treated with WLC alone. The total average cost per patient is $30,581 in the white light arm and $25,921 in the BLC with Cysview® arm. Those patients who initially receive BLC TURB with Cysview® also experience an 11% improvement in overall cancer burden over five years.  This was supported by the lower recurrence rates leading to less muscle invasive disease as demonstrated in the Grossman study.

  1. Grossman HB, Stenzl A, Fradet Y et al. Long term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012; 188(1): 58-62

Links
Publication by J. Stephen Jones et al

Cysview® prescribing information

About Cysview®/Hexvix®
Cysview®/Hexvix® is the first approved drug-device combination procedure for improved detection and management of bladder cancer. It is designed to induce fluorescence in the malignant cells in the bladder during a cystoscopic procedure, making it easier for the urologist to detect non muscle invasive bladder cancer, as an adjunct to white light cystoscopy. It is the first product in a new diagnostic class known as Photodynamic Diagnostic (PDD) agents. Hexvix®/Cysview® is an approved product in Europe and the US.  Photocure markets and sells Hexvix® in the Nordic region, and has initiated the commercialization of Cysview® directly in the US. Ipsen is commercializing Hexvix® in Europe excluding Nordics.

For further information, please contact:
Photocure
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no

 CFO Erik Dahl
Tel: +47 50 55 000, Email: ed@photocure.no

About Photocure ASA
Photocure ASA, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology™ platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions which can improve health outcomes for patients worldwide. Information about Photocure is available at www.photocure.com.

Photodynamic technology is the application of a photosensitizer followed by exposure to light for activation
HPV: human papillomavirus
Photocure Technology® is Photocure’s specifically designed photosensitizers combined with the exposure to light for diagnosis and/or treatment of specific conditions.

All trademarks mentioned in this release are protected by law and registered trademarks of Photocure.